Sun Yat-sen University Cancer Center

Name: Qi-Feng Chen

Title: Associate Professor, Associate chief physician

Email: chenqf25@sysucc.org.cn

Phone:

share

Profile

The research program ofQi-Feng Chen, MD, has focused on the clinical and translational research of liver cancer. Dr.Chenhas long beeninvolved in the clinical and translational research of interventional oncology and comprehensive cancer treatment. He is proficient in various minimally invasive interventional techniques for cancer treatment.

Dr.Chen has alsocarriedout several modeling studies and proposed a survival prediction modelfor liver cancer patients. He hasadditionally conducted a multistate Markov model study andexplored the impact of liver cancer surveillance on the overall survivalof patients with cirrhosis after ablation.

Moreover, Dr.Chen hasshown interest in liver cancer healtheconomic research from a global perspective. Finally, Dr.Chen has been interested in liver cancerimmunotherapy andbiomarker research.

Interests

Minimally invasive interventional therapy and comprehensive management of liver cancers; image-guided minimally invasive therapies (intervention, ablation) for solid tumors.

Education

Doctor’s degree, Sun Yat-sen University, China, September 2017 to June 2020

Master’s degree, Nanjing Medical School, China, September 2014 to June 2017

Bachelor's degree, Chongqing Medical School, China, September 2009 to June 2014

Publications

1. Chen QF, et al. Hepatocellular Carcinoma Surveillance: A Health Economic Evaluation. Clin Mol Hepatol. (2025 JCR Q1, IF 16.9)

2. Chen QF, et al. Hepatic Artery Infusion Chemotherapy (HAIC) for Cholangiocarcinoma in 2025. Liver Cancer. (2025 JCR Q1, IF 9.1)

3. Chen QF, et al. Reply to "Correspondence to Economic and Clinical Considerations for NC-MRI in Late HCC Recurrence Surveillance". Clin Mol Hepatol. (2025 JCR Q1, IF 16.9)

4. Chen QF, et al. Beyond Diagnostic Accuracy: Economic and Clinical Considerations for NC-MRI in Late HCC Recurrence Surveillance. Clin Mol Hepatol. (2025 JCR Q1, IF 16.9)

5. Chen QF, et al. Immunotherapy versus lenvatinib in hepatocellular carcinoma: the need for granular data and prospective validation. J Immunother Cancer. 2025;13(8):e012560. (2025 JCR Q1, IF 10.1)

6. Chen QF, et al. Children's hepatoblastoma: gender and infant age demand focus in the global burden of disease study 2021. Hepatol Int. 2025;19(6):1490-1492. (2025 JCR Q1, IF 6.1)

7. Chen QF, et al. Recommended 10-Year Follow-Up Strategy for Small Hepatocellular Carcinoma After Radiofrequency Ablation: A Cost-Effectiveness Evaluation. Am J Gastroenterol. 2024;119(10):2052-2060. (2025 JCR Q1, IF 8.1)

8. Chen QF, et al. Cost-effectiveness and prognostic model of hepatic arterial infusion chemotherapy for hepatocellular carcinoma with high tumor burden and/or Vp4 tumor thrombus compared with sorafenib: a post-hoc analysis of the FOHAIC-1 trial. Int J Surg. 2023;109(12):3929-3939. (2025 JCR Q1, IF 10.3)

9. Chen QF, et al. Surveillance Strategy after Complete Ablation of Initial Recurrent Hepatocellular Carcinoma: A Risk-Based Machine Learning Study. J Vasc Interv Radiol. 2021;32(11):1548-1557.e2. (2025 JCR Q2, IF 2.6)

10. ...Chen QF. Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study. Front Immunol. 2020;11:2048. (2025 JCR Q1, IF 5.9)

Our Experts